Catalyst Pharmaceuticals (CPRX) Gross Margin (2019 - 2026)
Catalyst Pharmaceuticals' (CPRX) quarterly Gross Margin came in at 90.31% in Q1 2026, up 298.0% YoY from 22.69% in Q1 2025, and up 8.92% on a QoQ basis from 82.91% in Q4 2025.
Powered by 
Analysis
Catalyst Pharmaceuticals (CPRX) Gross Margin (2019 - 2026) Analysis & Trends
Catalyst Pharmaceuticals (CPRX) has 8 years of Gross Margin data on file, last reported at 90.31% in Q1 2026.
- Quarterly Gross Margin rose 298.0% year-over-year to 90.31% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 85.96% (down 16.0% YoY) and the FY2025 annual result came in at 85.19%, down 81.0% from the prior year.
- Gross Margin advanced to 90.31% in Q1 2026, from 82.91% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 90.31% in Q1 2026 to a low of 81.57% in Q4 2022.
- A 5-year average of 85.91% and a median of 85.94% in 2025 frame the typical range for Gross Margin.
- Annual changes were most pronounced in 2022 — Gross Margin slumped 211 bps — and 2023, when it jumped 413 bps.
- Tracing CPRX's Gross Margin over 5 years: stood at 81.57% in 2022, then advanced by 5 bps to 85.7% in 2023, then retreated by 1 bps to 84.74% in 2024, then declined by 2 bps to 82.91% in 2025, then gained by 9 bps to 90.31% in 2026.
- The last three Gross Margin figures came in at 90.31% (Q1 2026), 82.91% (Q4 2025), and 84.73% (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 35.86% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 89.76% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 76.90% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 84.20% |
| 10 | Catalyst Pharmaceuticals | 3.85 Bn | 3.09 Bn | 134.92 Mn | 90.31% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 90.31% |
| Dec 31, 2025 | 82.91% |
| Sep 30, 2025 | 84.73% |
| Jun 30, 2025 | 85.94% |
| Mar 31, 2025 | 87.33% |
| Dec 31, 2024 | 84.74% |
| Sep 30, 2024 | 85.02% |
| Jun 30, 2024 | 87.45% |
| Mar 31, 2024 | 87.29% |
| Dec 31, 2023 | 85.70% |
| Sep 30, 2023 | 86.20% |
| Jun 30, 2023 | 87.90% |
| Mar 31, 2023 | 88.35% |
| Dec 31, 2022 | 81.57% |
| Sep 30, 2022 | 83.12% |
| Jun 30, 2022 | 85.61% |
| Mar 31, 2022 | 86.33% |
| Dec 31, 2021 | 80.82% |
| Sep 30, 2021 | 85.23% |
| Jun 30, 2021 | 87.50% |